University of Tours, Inserm U1069 Nutrition, Croissance et Cancer (N2C), Faculty of Medicine, 10 Boulevard Tonnellé, 37032, Tours Cedex, France.
University of Nantes, CNRS, Faculty of Sciences, Chimie et Interdisciplinarité: Synthèse, Analyse, Modélisation (CEISAM), UMR CNRS 6230, 2, Rue de La Houssinière, 44322, Nantes Cedex 3, France.
Eur J Med Chem. 2020 Jan 15;186:111854. doi: 10.1016/j.ejmech.2019.111854. Epub 2019 Nov 9.
Small Conductance Calcium (Ca)-activated potassium (K) channels (SKCa) are now proved to be involved in many cancer cell behaviors such as proliferation or migration. The SK3 channel isoform was particularly described in breast cancer where it can be associated with the Orai1 Ca channel to form a complex that regulates the Ca homeostasis during tumor development and acts as a potent mediator of bone metastases development in vivo. Until now, very few specific blockers of Orai1 and/or SK3 have been developed as potential anti-metastatic compounds. In this study, we illustrated the synthesis of new families of lipophilic pyridine and tetrahydropyridine derivatives designed as potential modulators of SK3 channel. The toxicity of the newly synthesized compounds and their migration effects were evaluated on the breast cancer cell line MDA-MB-435s. Two molecules (7a and 10c) demonstrated a significant decrease in the SK3 channel-dependent migration as well as the SK3/Orai1-related Ca entry. Current measurements showed that these compounds are more likely SK3-selective. Taken all together these results suggest that such molecules could be considered as promising anti-metastatic drugs in breast cancer.
小电导钙激活钾 (SKCa) 通道现已被证明参与许多癌细胞行为,如增殖或迁移。SK3 通道亚型在乳腺癌中特别描述,它可以与 Orai1 钙通道形成复合物,调节肿瘤发展过程中的钙稳态,并作为体内骨转移发展的有力介质。到目前为止,很少有针对 Orai1 和/或 SK3 的特异性阻滞剂被开发为潜在的抗转移化合物。在这项研究中,我们说明了新的亲脂性吡啶和四氢吡啶衍生物家族的合成,这些衍生物被设计为 SK3 通道的潜在调节剂。新合成化合物的毒性及其对乳腺癌细胞系 MDA-MB-435s 的迁移作用进行了评估。两种分子(7a 和 10c)显示出 SK3 通道依赖性迁移以及 SK3/Orai1 相关 Ca 内流的显著减少。电流测量表明,这些化合物更可能是 SK3 选择性的。综上所述,这些结果表明,此类分子可被视为乳腺癌有前途的抗转移药物。